Strides Pharma Science Limited has informed the Exchange regarding a press release dated October 30, 2023, titled "Strides reports Strong Q2FY24 Performance Revenues at ₹ 10,264m and EBITDA at ₹ 1,801m".
Press Release Oct 30 2023
Filed with NSE ·
6ix hasn’t read this filing yet.
Strides Pharma Science Ltd on 6ix
Earlier from Strides Pharma Science
- Press Release Oct 04 2023
- Press Release (Revised) Oct 03 2023
- Press Release Sep 23 2023
- Intimation of Board Meeting scheduled on Sept 25, 2023
- Press Release Sep 14 2023
Later from Strides Pharma Science
- Press Release Nov 21 2023
- Strides Pharma Science Ltd Press Release Nov 23 2023
- Press Release Dec 01 2023
- Press Release Jan 25 2024
- Press Release Jan 30 2024
Follow Strides Pharma Science into a list and get an email when it puts out news.
Follow Strides Pharma Science